Novo Nordisk Sways Jury to Reject Whistleblower’s Fraud Suit (2)

Novo Nordisk Inc. convinced a jury to reject claims that the pharmaceutical giant defrauded Washington state’s Medicaid by improperly billing the health-care program for its hemophilia drug NovoSeven.

The government and whistleblower Jamie Siegel didn’t demonstrate that the company violated the False Claims Act, according to a Nov. 7 judgment on jury verdict that followed a 15-day trial.

“The most important thing about a jury trial is a public record,” said Siegel’s attorney, Reuben A. Guttman of Guttman, Buschner & Brooks PLLC.

“The jury’s decision is about whether the conduct fits into a sliver of law,” he said. “The record, ...